TICKERNERD
Menu
BAXBAXHealthcare · Medical Instruments & Supplies

BAX Stock Forecast: Baxter International, Inc. Price Predictions for 2026-2027

Last close, 17 Aug 2026
$26
−3.07% on the day

The 13 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $28 — +8.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$13.8B
Ticker Nerd rank
89 / 100
Median analyst target
$28
Analysts covering
13
Total return, dividends reinvested
1W
−6.7%
1M
+14.6%
YTD
+35.7%
1Y
+8.1%
From 52W high
−8.6%
From 52W low
+64.1%
$16
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Accruals
95
Revisions
91
Issuance
85
Volatility
69
Growth
58
Quality
49
Momentum
39
Size
13

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (39): The shares have been drifting down relative to others.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26BAXHigh $40Median $28Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
2 Buy11 Hold0 Sell
Low $23Median $28High $40

The green dot is the last close — the median target sits +8.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 July 2026CitigroupUpgradeNeutral$17 → $28
31 July 2026StifelMaintainsHold$24 → $28
31 July 2026TD CowenMaintainsHold$24 → $29
31 July 2026Wells FargoMaintainsEqual-Weight$19 → $23
28 July 2026StifelMaintainsHold$19 → $24
28 July 2026UBSMaintainsNeutral$19 → $25
27 July 2026TD CowenMaintainsHold$20 → $24
15 July 2026Goldman SachsMaintainsNeutral$19 → $21
15 July 2026Goldman SachsMaintainsNeutral—
6 July 2026Evercore ISI GroupMaintainsOutperform$22 → $24
6 July 2026Evercore ISI GroupMaintainsOutperform—
28 May 2026CitigroupDowngradeSell—
4 May 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026CitigroupMaintainsNeutral—
17 Feb 2026Goldman SachsMaintainsNeutral—
13 Feb 2026BarclaysMaintainsOverweight—
9 Jan 2026BarclaysMaintainsOverweight—
2 Dec 2025Morgan StanleyMaintainsUnderweight—
31 Oct 2025Argus ResearchDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.7%
Analysts raising
6
Analysts cutting
2
Fundamentals

Baxter International, Inc. (BAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
86.3×

Cheaper than 9% of US stocks

Price / sales
1.2×

Cheaper than 66% of US stocks

Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
11.3×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
5.3%

Higher than 40% of US stocks

Earnings growth (YoY)
38.5%

Higher than 71% of US stocks

Gross margin
34.9%

Higher than 43% of US stocks

Operating margin
14.4%

Higher than 71% of US stocks

Net margin
−9.3%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−14.4%

Higher than 34% of US stocks

Return on assets
2.8%

Higher than 64% of US stocks

Dividend yield
0.1%

Higher than 2% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BAXBaxter International, Inc.$13.8B
89
ALGNAlign Technology, Inc.$12.3B
82
COOThe Cooper Cos., Inc.$14.7B
77
SOLVSolventum Corp.$15.1B
89
RGENRepligen Corp.$9.5B
90
AVTRAvantor, Inc.$9.2B
79
ATRAptarGroup, Inc.$8.6B
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BAX news & analysis

Baxter Announces Pricing for Its Upsized Cash Tender Offers

Business Wire · 18 Aug 2026neutral

Baxter International announced the pricing terms for its previously announced cash tender offers for certain of its notes, using a "waterfall" methodology under which the Company will accept validly tendered notes in order of their respective acceptance priority levels. The offers were upsized from their initial size.

Why it matters — The tender offers reflect Baxter's debt-management activity, which Baxter watchers would track for its potential impact on the company's capital structure and liabilities.

Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers

Business Wire · 18 Aug 2026neutral

Baxter International announced the early results of its previously announced cash tender offers for certain notes, which were made pursuant to an Offer to Purchase dated Aug. 4, 2026. The company also reported an upsizing of the tender offers.

Why it matters — The tender offer results and upsizing reflect Baxter's ongoing debt-management activities, which are relevant to investors tracking the company's capital structure.

Baxter Announces Cash Tender Offers

Business Wire · 4 Aug 2026neutral

Baxter International announced it has commenced cash tender offers to purchase a maximum aggregate principal amount of its notes, with the aggregate purchase price (excluding accrued and unpaid interest) not to exceed $500 million.

Why it matters — BAX watchers would care because this debt-management move affects the company's capital structure and outstanding liabilities.

Baxter International: The Gains Can Continue, But Should Slow

Seeking Alpha · 3 Aug 2026positive

According to a Seeking Alpha article, Baxter International has shown early signs of a turnaround, with improved execution and raised revenue guidance. The piece notes the stock's valuation has expanded from distressed levels to roughly 13x earnings and 9.5x EV/EBITDA but remains attractive if growth continues, with management focused on operational improvements and cost savings.

Why it matters — BAX watchers would care because the article suggests the company is showing early turnaround signs and cautiously optimistic momentum, while flagging that valuation-driven gains may begin to slow.

Why Baxter International Stock Skyrocketed by 19% This Week

The Motley Fool · 1 Aug 2026positive

Baxter International's stock rose 19% this week after the company beat analyst estimates on both the top and bottom lines, and it raised its guidance for revenue and earnings.

Why it matters — A Baxter watcher would care because the company exceeded analyst expectations and lifted its financial outlook, signaling stronger operating performance than the market had anticipated.

FAQ

Frequently asked questions about BAX stock

What is the BAX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $28, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BAX stock a buy right now?

Of the 13 analysts covering Baxter International, Inc., 2 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 89 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BAX?

As at 17 Aug 2026, Baxter International, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will BAX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +8.1% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 89 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BAX stock forecast for 2030?

No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has BAX stock performed over the past year?

Baxter International, Inc. returned +8.1% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Baxter International, Inc. do?

Baxter International Inc. is a healthcare company that provides essential medical products and therapies used in hospitals, clinics, and home care settings.

What is the latest news on BAX?

The most recent item we track (Business Wire, 18 Aug 2026): "Baxter Announces Pricing for Its Upsized Cash Tender Offers". Baxter International announced the pricing terms for its previously announced cash tender offers for certain of its notes, using a "waterfall" methodology under which the Company will accept validly tendered notes in order of their respective acceptance priority levels. The offers were upsized from their initial size.

Company

About Baxter International, Inc.

Baxter International Inc. is a healthcare company that provides essential medical products and therapies used in hospitals, clinics, and home care settings. Baxter International Inc. offers acute and chronic dialysis treatments, sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, and surgical products such as hemostats and sealants. The company also supplies smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Its portfolio supports critical care, perioperative care, renal care, and medication delivery across a broad range of healthcare environments. Baxter International Inc. serves healthcare providers and patients with products designed to support treatment, monitoring, and recovery in routine and specialized medical settings. Headquartered in Deerfield, Illinois, Baxter International Inc. plays a significant role in the global medical products market.

CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com